Nuevos sistemas de liberación controlada de tolcapona para el tratamiento de la enfermedad de Parkinson

Abstract

Parkinson's disease (PD) is a complex neurodegenerative disorder with a heterogeneous presentation. To date there is no cure for the disease however, there are several drugs that can act controlling the symptoms along the progression of the disease in order to maintain the quality of life of the patients. Furthermore, given that it is the second most common neurodegenerative disorder after Alzheimer's disease, and that its main risk factor is age, Parkinson's disease is increasingly posing a public health challenge.Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that is administered with levodopa to control motor fluctuations in PD. Selective and reversible inhibition of COMT leads to a reduction in the catabolism of levodopa to 3-O-methyldopa, resulting in increased availability of dopamine in the brain, thereby allowing for a reduction of total daily dose of levodopa...